Find a Doctor or Practice Location

Are you a referring physician?
within
I am searching for a
Reset Form
Aimee S. Payne, MD, PhD

Aimee S. Payne, MD, PhD Physician

Albert M. Kligman Associate Professor of Dermatology

Dr. Payne is a Penn Medicine employed physician.

Clinical Specialties

Specialty:

  • Dermatology

Programs & Centers:

Board Certification:

  • Dermatology, 2005

Clinical Expertise:

  • Dermatitis Herpetiformis (Duhring's Disease)
  • Mole Check
  • Pemphigus
  • Skin Cancer

Description of Clinical Expertise

Medical Dermatology
Blistering Skin Diseases

Practice Locations and Appointments

  • Penn Dermatology

    Perelman Center for Advanced Medicine South Pavilion, 1st Floor 3400 Civic Center Boulevard Philadelphia, PA 19104 800-789-PENN (7366)

    A facility of the Hospital of the University of Pennsylvania

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • CVS Health
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthPartners Medicare
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Health Care/LGH
  • Rail Road Medicare / Palmetto GBA
  • Remedy Partners at Penn Medicine
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Washington University
Residency: Pennsylvania Hospital
Residency: Hospital of the University of Pennsylvania

Memberships

Dermatology Foundation, National Deutsche Forschungsgemeinschaft, International International Pemphigus and Pemphigoid Foundation, International Israel Science Foundation, International NIH study section ad-hoc reviewer, ZRG1/ACTS, National Society for Investigative Dermatology, International Syntimmune, National TG Therapeutics, National

Hospital Affiliation

Dr. Payne is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
  • Penn Presbyterian Medical Center: Has privileges to treat patients in the hospital.

Research

Description of Research Expertise:

Research Interests:
Genetic and functional characterization of human anti-desmoglein B cell repertoires
Targeted therapy for pemphigus
Regulation of desmosome adhesion

Key words: autoimmunity, human immunology, CAR T cells, adoptive immunotherapy, cell adhesion, dermatology, skin, cadherin, p38 MAPK

Description of Research:
Pemphigus vulgaris is a potentially fatal disorder in which autoantibodies against desmosomal cell adhesion molecules known as desmogleins cause blistering of the skin and mucous membranes. Our laboratory is interested in better understanding pathogenic mechanisms in this model organ-specific autoimmune disease, from both the immunologic and cell biologic perspectives.

A fundamental question in organ-specific autoimmune disease is why the immune system breaks tolerance against only a limited number of self-antigens. We have cloned B cell repertoires from pemphigus vulgaris patients to understand how they developed desmoglein autoreactivity. We have identified shared VH1-46 gene usage in anti-desmoglein 3 B cells from different pemphigus patients and defined acidic amino acid residues that are necessary and sufficient to confer desmoglein 3 autoreactivity. These VH1-46 B cells are autoreactive to the disease antigen in the absence of somatic mutation or require very few mutations to develop autoreactivity, which may favor their selection early in the immune response. Common VH gene usage is significant, because it may indicate common mechanisms for developing autoimmunity in pemphigus vulgaris. Ongoing projects aim to identify common features of the autoimmune response to desmogleins and the immune response to foreign antigens, perform lineage tracing of pemphigus autoantibody repertoires, and characterize the B cell subsets that produce the pathogenic autoantibodies.

Ultimately, a better understanding of the shared structural elements of pemphigus B cell repertoires (e.g., VH or CH gene usage) can lead to better targeted therapies for disease. Current methods for treating autoimmunity require general immune suppression to reduce antibody production, but this approach impairs protective immune responses, which can lead to potentially fatal infections and secondary cancers. We recently described a novel method for re-engineering chimeric antigen receptor T cells for targeted immunotherapy of pemphigus vulgaris. By using the pemphigus autoantigen desmoglein 3 as the extracellular domain (the “bait”) on a chimeric autoantibody receptor (CAAR), we can direct a patient’s T cells to specifically seek out and kill the pemphigus-specific B cells, while sparing the good immune cells that protect from infection. We are currently in the process of moving forward CAAR technology to clinical trials in dogs and humans with pemphigus. The full text of this work is available at Science online.

Our laboratory is also investigating the cell regulatory pathways that promote desmosomal adhesion. We have shown that the p38 MAPK/MK2 axis is a critical regulator of desmosomal adhesion in keratinocytes and that inhibition of this pathway can ameliorate pemphigus skin blistering. Ongoing projects are studying the regulation of desmosomal adhesion and desmosomal protein expression in keratinocytes to better understand how anti-desmoglein antibodies cause the loss of cell adhesion and how we might interfere with these pathways to improve disease.

Lab personnel:
Xuming Mao, MD/PhD, senior research investigator
Christoph Ellebrecht, MD, postdoctoral fellow
Eun Jung Choi, MS, research specialist
Eric Mukherjee, CAMB/MSTP thesis student
Nina Ran, Masters in Translational Research thesis student
Michael Stephens, MS2 student

Lab alumni (current position):
Preety M. Sharma, PhD (Associate Research Scientist, Columbia University)
Takeru Funakoshi, MD, PhD (Dermatology faculty, Keio University, Japan)
Luisa Lunardon, MD (Dermatology faculty, University of Milan)
Arielle R. Nagler, MD (Dermatology faculty, New York University)
Michael Jeffrey Cho, PhD (Healthcare consultant)
Sara A. Farber, MD (Dermatology resident, University of Pennsylvania)
Courtney B. Rubin, MD (Medicine Intern)

Other Penn Appointments:
Associate Director, Medical Scientist Training Program
Immunology Graduate Group
Cell and Molecular Biology Graduate Group
Institute for Translational Medicine and Therapeutics

Selected Publications:

Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, Di Zenzo G, Lanzavecchia A, Seykora JT, Cotsarelis G, Milone MC, Payne AS: Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease Science 353 : 179-184,2016.

Cho MJ, Ellebrecht CT, Hammers CM, Mukherjee EM, Sapparapu G, Boudreaux CE, McDonald SM, Crowe JE, Jr., Payne AS.: Determinants of VH1-46 cross-reactivity to pemphigus vulgaris autoantigen desmoglein 3 and rotavirus antigen VP6 J. Immunol. 197 (4): 1065-73,2016.

Cho MJ, Ellebrecht CT, Payne AS: The dual nature of interleukin 10 in pemphigus vulgaris Cytokine 73 : 335-341,2015.

Cho MJ, Lo ASY, Mao X, Nagler AR, Ellebrecht CT, Mukherjee EM, Hammers CM, Choi EJ, Sharma PM, Uduman M, Li H, Rux AH, Farber SA, Rubin CB, Kleinstein SH, Sachais BS, Posner MR, Cavacini LA, Payne AS: Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients Nature Commun. 5 : 4167,2014.

Ellebrecht CT, Choi EJ, Allman DM, Tsai DE, Wegener WA, Goldenberg DM, Payne AS: Subcutaneous veltuzumab, a humanized anti-CD20 antibody, for treatment of refractory pemphigus vulgaris JAMA Dermatol. 150 : 1331-1335,2014.

Mao X, Li H, Sano Y, Gaestel M, Park JM, Payne AS.: MAPKAP kinase 2 (MK2)-dependent and independent models of blister formation in pemphigus vulgaris. J. Invest. Dermatol. 134 : 68-76,2014.

Funakoshi T, Lunardon L, Ellebrecht CT, Nagler AR, O’Leary CE, Payne AS.: Enrichment of total serum IgG4 in pemphigus patients Br.J.Dermatol. 167 : 1245-1253,2012.

Lunardon L, Payne AS.: Inhibitory human anti-chimeric antibodies to rituximab in a pemphigus patient J.Allerg.Clin.Immunol. 130 : 800-803,2012.

Lunardon L, Tsai KJ, Propert KJ, Fett N, Stanley JR, Werth VP, Tsai DE, Payne AS.: Adjuvant rituximab therapy of pemphigus: a single center experience with 31 patients. Arch.Dermatol. 148 (9): 1031-1036,2012.

Murrell DF, Dick S, Ahmed AR, Amagai M, Barnadas MA, Borradori L, Bystryn JC, Cianchini G, Diaz L, Fivenson D, Goldsmith L, Hall R, Harman K, Hashimoto T, Hertl M, Hunzelmann N, Iranzo P, Joly P, Jonkman M, Kitajima Y, Korman N, Martin LK, Mimouni D, Payne AS, Rubenstein D, Shimizu H, Sinha A, Sirois D, Zillikens D, Werth VP: Consensus statement on definitions of disease endpoints and therapeutic response for pemphigus Journal of the American Academy of Dermatology 58 : 1043-1046,2008.

View all publications

Academic Contact Info

1009 Biomedical Research Building
421 Curie Boulevard

Philadelphia, PA 19104
Phone: (215) 662-2737
Fax: (215) 573-7173
Patient appointments: 800-789-PENN (7366)

Related Links